AWARD assessment of weekly administration of LY2189265 in diabetes (dulaglutide, 0.75 mg or 1.5 mg QW), BS bariatric surgery, BMI body mass index, DURATION diabetes therapy utilization: researching changes in A1C, weight and other factors through intervention with exenatide QW (extended-release exenatide, 2 mg, once weekly), EQW exenatide QW, FM fat mass, GETGOAL GLP-1 agonist AVE0010 in patients with type 2 diabetes mellitus for glycaemic control and safety evaluation (lixisenatide, 20 g once daily), GLP-1 RA glucagon-like peptide-1 receptor agonist, HbA1c glycated haemoglobin, HD haemodialysis, LEAD liraglutide effect and action in diabetes (liraglutide 1.2 mg or 1.8 mg daily), OAD oral antidiabetics, RCT randomised controlled trial, SCALE satiety and clinical adiposityliraglutide evidence in individuals with and without diabetes, SGLT2 sodium-glucose co-transporter-2, SMM skeletal muscle mass, SUSTAIN-6 trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes (semaglutide, 0.5 mg or 1.0 mg QW), T2DM type 2 diabetes mellitus, WMD weighted mean difference Cardiovascular Health GLP-1 RAs have been reported to be beneficial for cardiovascular health in patients with T2DM as these drugs aid in controlling cardiovascular (CV) risk factors such as hyperglycaemia, dyslipidaemia, weight gain and arterial hypertension (Tables 14, 15)
Gourine, A
For example, these foods contribute to leaky gut syndrome, which we know is present in nearly everyone with Hashimotos
Collado-Mateo D, Lavn-Prez AM, Merellano-Navarro E, Coso JD (2020) Effect of acute caffeine intake on the fat oxidation rate during exercise: a systematic review and meta-analysis
What postacquisition initiatives (e.g., development, go to market) are required to accelerate the realization of full potential
As users get more sophisticated in how they interact with LLMs and start injecting personas into the prompt, that layering is becoming the norm, not the exception
